Human Immune Responses to The Yellow Fever Virus Vaccine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00694655|
Recruitment Status : Active, not recruiting
First Posted : June 10, 2008
Last Update Posted : October 18, 2019
The objective of this study is to study immune memory generated against the yellow fever vaccine (YFV) in participants who recently received the YFV vaccine. Volunteers who are planning to travel to yellow fever endemic areas will be recruited into this study. Volunteers will receive the yellow fever vaccine at the Hope Clinic of Emory University or at their private health care provider's office. Blood tests will be drawn before the vaccination and at upto 8 visits following vaccination. A volunteers's study participation may will last as short as 1 month or as long as one year depending on the immune responses.
We plan to compare the immune responses in younger people (18 to 45 years) to that of older people (55 or above).
|Condition or disease||Intervention/treatment||Phase|
|Yellow Fever||Biological: Yellow fever vaccine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Human Immune Responses to Yellow Fever Vaccination|
|Study Start Date :||May 2008|
|Estimated Primary Completion Date :||December 2025|
|Estimated Study Completion Date :||December 2025|
There are no arms for this study. All participants will receive the YFV vaccine if they meet the screening criteria.
Biological: Yellow fever vaccine
YFV will be given as injection
Other Name: YF-VAX
- 1. Isolation and characterization of yellow fever vaccine (YFV-17D) specific adaptive immune responses: characterize the magnitude and quality of YFV specific T cell responses, antibody secreting cells and memory B cells. [ Time Frame: Upto 12 months after vaccination ]Compare the magnitude and quality of YFV-specific immune responses in the younger and older age groups.
- Determine the signatures of innate immune responses: cytokines, chemokines, dendritic cells and microarray analyses on peripheral blood mononuclear cells [ Time Frame: Upto 12 months after vaccination ]Compare the magnitude and kinetics of T and B cell responses, antibody secreting cells and memory B cells in the younger and the older age groups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00694655
|United States, Georgia|
|The Hope Clinic of the Emory Vaccine Center|
|Decatur, Georgia, United States, 30030|
|Study Chair:||Rafi Ahmed, PhD||Emory University|
|Principal Investigator:||Sri Edupuganti, MD, MPH||Emory University|